

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Single Technology Appraisal (STA)

## Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Wyeth Pharmaceuticals (temsirolimus)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• African and Caribbean Leukaemia Trust</li> <li>• Anthony Nolan Bone Marrow Trust</li> <li>• Black Health Agency</li> <li>• CANCERactive</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Leukaemia CARE</li> <li>• Leukaemia Society</li> <li>• Lymphoma Association</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• National Cancer Alliance</li> <li>• National Council for Palliative Care</li> <li>• Rarer Cancers Forum</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Baxter (cyclophosphamide, mitoxantrone)</li> <li>• Bayer (alemtuzumab, fludarabine)</li> <li>• Bristol-Myers Squibb (etoposide)</li> <li>• Celgene (lenalidomide, thalidomide)</li> <li>• Cephalon (doxorubicin)</li> <li>• GlaxoSmithKline (chlorambucil)</li> <li>• Goldshield Pharmaceuticals (methotrexate)</li> <li>• Hospira UK (etoposide, cytarabine, doxorubicin, vinblastine, vincristine, methotrexate)</li> <li>• Janssen-Cilag (cladribine)</li> <li>• Eli Lilly (gemcitabine, vinblastine, vincristine)</li> <li>• Lipomed (cladribine)</li> </ul>

National Institute for Health and Clinical Excellence

Matrix for the technology appraisal of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma

Issue date: November 2009

Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Association for Services to the Elderly</li> <li>• British Blood Transfusion Society</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Oncological Association (BOA)</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• National Blood Service</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians, Medical Oncology Joint Special Committee</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Herefordshire PCT</li> <li>• Swindon PCT</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Medac UK (doxorubicin, etoposide, methotrexate)</li> <li>• Napp Pharmaceuticals (cytarabine)</li> <li>• Pfizer (cyclophosphamide, cytarabine, doxorubicin, methotrexate)</li> <li>• PLIVA UK (mitoxantrone)</li> <li>• Roche (rituximab)</li> <li>• Schering Health (alemtuzumab)</li> <li>• Schering-Plough (doxorubicin)</li> <li>• Teva UK (fludarabine, doxorubicin, etoposide, methotrexate, mitoxantrone)</li> <li>• Wockhardt (doxorubicin, methotrexate, mitoxantrone)</li> <li>• Wyeth (mitoxantrone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Elimination of Leukaemia Fund</li> <li>• Institute of Cancer Research</li> <li>• Leukaemia Research Fund</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute of the Care Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> <li>• Peninsula Technology Assessment Group, University of Exeter (PenTAG)</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination.  
Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.